AC Immune reports 12-month interim data from ABATE trial of ACI-24
The Phase 1b/2 trial showed antibody dose response with no ARIA-E across the first three Alzheimer's cohorts, while a fourth cohort testing an added adjuvant is underway.
AC Immune SA announced on June 30, 2026 interim 12-month data from the first three cohorts of its Phase 1b/2 ABATE trial testing ACI-24, an anti-Abeta active immunotherapy, in patients with prodromal Alzheimer's disease. The data cover the first three cohorts, AD1, AD2 and AD3, totaling 74 patients with prodromal Alzheimer's disease.1
The company reported that ACI-24 has been generally safe and well tolerated so far, with no evidence of amyloid-related imaging abnormalities-edema, and that anti-Abeta antibody responses were detected at every dose level with a dose response.1 Based on the antibody response pattern observed, the company evaluated enhancing ACI-24 with an additional adjuvant to boost immunogenicity while the trial was ongoing, a design now being tested in the newly started Cohort AD4.1
Interim CEO Martin Zügel said the nature of the antibody response observed in ABATE suggests further enhancement of immunogenicity is needed for more effective plaque removal, and that Cohort AD4 was initiated to evaluate ACI-24 with the additional adjuvant.1
The ABATE trial is described as a randomized, double-blind, placebo-controlled Phase 1b/2 study of ACI-24 in prodromal AD and in adults with Down syndrome, with enrollment in the third Down syndrome cohort, DS3, now concluded (NCT05462106).1 Multiple data safety monitoring board reviews have raised no safety concerns to date, consistent with the absence of ARIA findings in earlier results.1
The program is partnered with Takeda. Under the license agreement, AC Immune received a $100 million upfront payment and a $12 million milestone tied to dosing the first patients in Cohort AD4, and is eligible for further payments of up to approximately $2.1 billion plus tiered double-digit royalties on worldwide sales if commercialized.1 AC Immune remains responsible for running the ABATE trial, while Takeda would take over development, regulatory and commercialization responsibilities if it exercises its option.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.